Application of doxorubicin-induced rAAV2-p53 gene delivery in combined chemotherapy and gene therapy for hepatocellular carcinoma

Cancer Biology and Therapy

Volumn 7, Issue 2, 2008, Pages 303-309

  Chen, Chun Ann ^a   Lo, Cheng Kai ^b   Lin, Bai Ling ^b   Sibley, Eric ^c   Tang, Shiue Cheng ^a  

^a NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^b DEVELOPMENT CENTER FOR BIOTECHNOLOGY   (Taiwan)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy; Doxorubicin; Gene therapy; Hepatocellular carcinoma; Liver cancer; p53; rAAV2

Indexed keywords

DOXORUBICIN; PARVOVIRUS VECTOR; PROTEIN P53; RECOMBINANT ADENO ASSOCIATED VIRUS SEROTYPE 2 VECTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL STRAIN HEK293; CELL STRAIN HEPG2; CELL VIABILITY; CONTROLLED STUDY; CULTURE MEDIUM; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; GENE EXPRESSION; GENE TRANSFER; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; LIVER CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

EID: 42549127904     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.7.2.5333     Document Type: Article

References (39)